Eugenio A. Debbia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eugenio A. Debbia has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Anna Marchese
2 shared publicationsGian Carlo Schito
From the Institute of Microbiology, University of Ancona Medical School, Ancona, the Institute of Microbiology, University of Genoa Medical School, Genoa, the Department of Microbiological Sciences, University of Catania Medical School, Catania, the Department of Pediatrics, “Regina Margherita” Children's Hospital, Turin, and the Department of MCA Biology, University of Camerino, Camerino, Italy
2 shared publicationsA. Marchese
Institute of Microbiology C.A. Romanzi, University of Genoa, 16132 Genoa, Italy
1 shared publicationA.M. Schito
Institute of Microbiology C.A. Romanzi, University of Genoa, 16132 Genoa, Italy
1 shared publicationDario Pavesio
From the Institute of Microbiology, University of Ancona Medical School, Ancona, the Institute of Microbiology, University of Genoa Medical School, Genoa, the Department of Microbiological Sciences, University of Catania Medical School, Catania, the Department of Pediatrics, “Regina Margherita” Children's Hospital, Turin, and the Department of MCA Biology, University of Camerino, Camerino, Italy
1 shared publicationElisabetta Maioli
1 shared publication
Latest Publications
- 1 January 2008
- Vol. 31 (1) , 37-46
In vitro interaction between mecillinam and piperacillin-tazobactam in the presence of azithromycin against members of the Enterobacteriaceae family and Pseudomonas aeruginosa.
Mecillinam was tested in vitro alone or in combination with piperacillin-tazobactam and azithromycin against representative species of the Enterobacteriaceae family and Pseudomonas aeruginosa to extend its antibacterial spectrum, and to protect mecillinam from inactivating enzymes taking advantage of the presence of tazobactam. Drug interactions were studied by microdilution method, by selection of spontaneous resistant mutants on agar plates containing the drugs in combination and by time kill experiments. Against Enterobacteriaceae mecillinam and piperacillin-tazobactam showed synergistic interaction in 24/60 tests carried out by microdilution technology, in 4/16 by selecting resistant mutants and in 5/9 by time-kill experiments. P. aeruginosa reacted indifferently to the drug combinations, with few exceptions, when azithromycin was present a reduction of the MICs were recorded. Mecillinam reacted favourably in vitro in combination with piperacillin-tazobactam against not only strains included in its antibacterial spectrum but also against resistant Morganella morganii, Proteus spp and P. aeruginosa. The addition of azithromycin (8 mg/L) was beneficial for the drug combination increasing the bactericidal effect in the great majority of the cases. Only systematic in vivo studies may establish the clinical significance and benefits of the present observations.
- 1 January 2008
- Vol. 31 (1) , 37-46
In vitro interaction between mecillinam and piperacillin-tazobactam in the presence of azithromycin against members of the Enterobacteriaceae family and Pseudomonas aeruginosa.
Mecillinam was tested in vitro alone or in combination with piperacillin-tazobactam and azithromycin against representative species of the Enterobacteriaceae family and Pseudomonas aeruginosa to extend its antibacterial spectrum, and to protect mecillinam from inactivating enzymes taking advantage of the presence of tazobactam. Drug interactions were studied by microdilution method, by selection of spontaneous resistant mutants on agar plates containing the drugs in combination and by time kill experiments. Against Enterobacteriaceae mecillinam and piperacillin-tazobactam showed synergistic interaction in 24/60 tests carried out by microdilution technology, in 4/16 by selecting resistant mutants and in 5/9 by time-kill experiments. P. aeruginosa reacted indifferently to the drug combinations, with few exceptions, when azithromycin was present a reduction of the MICs were recorded. Mecillinam reacted favourably in vitro in combination with piperacillin-tazobactam against not only strains included in its antibacterial spectrum but also against resistant Morganella morganii, Proteus spp and P. aeruginosa. The addition of azithromycin (8 mg/L) was beneficial for the drug combination increasing the bactericidal effect in the great majority of the cases. Only systematic in vivo studies may establish the clinical significance and benefits of the present observations.
- 1 December 2001
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 7 (4) , 335-342
Antibiotic Persistence: The Role of Spontaneous DNA Repair Response
Persisters are a small proportion of a bacterial population that exists in a physiological state permitting survival despite the lethal activity of antibiotics. To explain this phenomenon, it has been suggested that persisters are bacteria repairing spontaneous errors of DNA synthesis. To verify this assumption, Escherichia coli AB 1157 and its lexA3 derivative were exposed to a dose 6× MIC of various antibiotics representative of different molecular mechanisms of action (ampicillin, ceftriaxone, meropenem, amikacin, ciprofloxacin). Bacterial cell counts, after 24 hr of exposure to the antimicrobials, revealed a reduction of about 90% of viable organisms in the lexA3 strains in comparison to the lexA + . In several cases, the number of colony-forming units decreased below the limit of assay. This behavior was noted with all antibiotics used, alone or in combination (amikacin plus ceftriaxone and amikacin plus ciprofloxacin). The same experiments were repeated using E. coli AB1157 cultured in the presence of mitomycin C (0.25× MIC), and the number of survivors exceeded by about 90% the values found in the nonexposed control. In contrast, in the sulA background, mitomycin C reacted synergically with all the antibiotics tested causing a strong reduction of the survivors in comparison with the control. The addition of chloramphenicol (0.125× MIC), on the contrary, caused a reduction of the number of survivors of about 90%. These findings indicate that, when DNA repair is active (a mechanism known to block cell division), the number of survivors is greater than that observed with lexA3 . Thus, in addition to other possible explanations, persisters might be a fraction of bacteria that during antibiotic treatment are not growing because they are repairing spontaneous errors of DNA synthesis.
- 1 December 2001
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 7 (4) , 335-342
Antibiotic Persistence: The Role of Spontaneous DNA Repair Response
Persisters are a small proportion of a bacterial population that exists in a physiological state permitting survival despite the lethal activity of antibiotics. To explain this phenomenon, it has been suggested that persisters are bacteria repairing spontaneous errors of DNA synthesis. To verify this assumption, Escherichia coli AB 1157 and its lexA3 derivative were exposed to a dose 6× MIC of various antibiotics representative of different molecular mechanisms of action (ampicillin, ceftriaxone, meropenem, amikacin, ciprofloxacin). Bacterial cell counts, after 24 hr of exposure to the antimicrobials, revealed a reduction of about 90% of viable organisms in the lexA3 strains in comparison to the lexA + . In several cases, the number of colony-forming units decreased below the limit of assay. This behavior was noted with all antibiotics used, alone or in combination (amikacin plus ceftriaxone and amikacin plus ciprofloxacin). The same experiments were repeated using E. coli AB1157 cultured in the presence of mitomycin C (0.25× MIC), and the number of survivors exceeded by about 90% the values found in the nonexposed control. In contrast, in the sulA background, mitomycin C reacted synergically with all the antibiotics tested causing a strong reduction of the survivors in comparison with the control. The addition of chloramphenicol (0.125× MIC), on the contrary, caused a reduction of the number of survivors of about 90%. These findings indicate that, when DNA repair is active (a mechanism known to block cell division), the number of survivors is greater than that observed with lexA3 . Thus, in addition to other possible explanations, persisters might be a fraction of bacteria that during antibiotic treatment are not growing because they are repairing spontaneous errors of DNA synthesis.
- Open Access
- 1 October 1999
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 29 (4) , 869-873
Nationwide Survey in Italy of Treatment ofStreptococcus pyogenesPharyngitis in Children: Influence of Macrolide Resistance on Clinical and Microbiological Outcomes
Throat swab specimens were obtained from 3,227 children with symptoms of acute pharyngotonsillitis. After 14 to 21 days, a second throat swab specimen was obtained at a follow-up visit. Over 42% of the 934 strains of Streptococcus pyogenes isolated in the primary study were resistant to erythromycin, azithromycin, and clarithromycin. Eradication rates among the 668 patients who entered the follow-up study were as follows: 84.1%, penicillin recipients; 82.7%, cephalosporin recipients; and 71.7%, macrolide recipients. Among patients treated with macrolides, the eradication rate was ~80% when the infecting organisms were erythromycin-susceptible and ~60% when they were erythromycin-resistant. These results indicate substantial in vitro macrolide resistance among Italian isolates of S. pyogenes. However, at least for a minor self-limiting condition such as acute S. pyogenes pharyngitis, our findings point to a limited overall correlation between in vitro susceptibility (to penicillins, cephalosporins, or macrolides) and eradication in patients treated with these drugs and an even weaker correlation between in vitro resistance (to macrolides) and noneradication in patients receiving macrolide therapy.
- 1 October 1999
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 29 (4) , 869-873
Open AccessNationwide Survey in Italy of Treatment ofStreptococcus pyogenesPharyngitis in Children: Influence of Macrolide Resistance on Clinical and Microbiological Outcomes
Throat swab specimens were obtained from 3,227 children with symptoms of acute pharyngotonsillitis. After 14 to 21 days, a second throat swab specimen was obtained at a follow-up visit. Over 42% of the 934 strains of Streptococcus pyogenes isolated in the primary study were resistant to erythromycin, azithromycin, and clarithromycin. Eradication rates among the 668 patients who entered the follow-up study were as follows: 84.1%, penicillin recipients; 82.7%, cephalosporin recipients; and 71.7%, macrolide recipients. Among patients treated with macrolides, the eradication rate was ~80% when the infecting organisms were erythromycin-susceptible and ~60% when they were erythromycin-resistant. These results indicate substantial in vitro macrolide resistance among Italian isolates of S. pyogenes. However, at least for a minor self-limiting condition such as acute S. pyogenes pharyngitis, our findings point to a limited overall correlation between in vitro susceptibility (to penicillins, cephalosporins, or macrolides) and eradication in patients treated with these drugs and an even weaker correlation between in vitro resistance (to macrolides) and noneradication in patients receiving macrolide therapy.
- 1 August 1999
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 5 (8) , 488-495
In vitro activity of quinupristin/dalfopristin against selected bacterial pathogens isolated in Italy
- 1 August 1999
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 5 (8) , 488-495
In vitro activity of quinupristin/dalfopristin against selected bacterial pathogens isolated in Italy